The primary focus in the treatment of CML has been on improving the specificity and potency of TKIs to inhibit the activation of the BCR::ABL1 kinase and/or overcoming resistance driven by mutations in the BCR::ABL1 oncogene. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.